Cardiovascular disease and COPD: dangerous liaisons?
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD)
frequently occur together and their coexistence is associated with worse outcomes than …
frequently occur together and their coexistence is associated with worse outcomes than …
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
L Vanfleteren, LM Fabbri, A Papi… - … journal of chronic …, 2018 - Taylor & Francis
Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study
Background Long-acting β 2 agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are the recommended initial maintenance treatment for chronic obstructive …
(LAMAs) are the recommended initial maintenance treatment for chronic obstructive …
Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice
Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …
Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice
Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
[HTML][HTML] Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: a systematic review and …
C Xiong, Y Li, G Zhuang, Y Zeng, H Wei, C Li… - … Therapies in Medicine, 2021 - Elsevier
Objective Randomized clinical trials and published meta-analyses assessing the clinical
effectiveness of Chinese herbal medicine (CHM) on the treatment of stable chronic …
effectiveness of Chinese herbal medicine (CHM) on the treatment of stable chronic …
[HTML][HTML] Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database
JK Quint, J Montonen, DB Esposito, X He, L Koerner… - Advances in …, 2021 - Springer
Introduction In patients with chronic obstructive pulmonary disease (COPD), treatment with
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA) combination …
[HTML][HTML] PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, relieves airway hyperresponsiveness, mucus hypersecretion and inflammation in a murine …
W Li, L Xue, C Peng, P Zhao, Y Peng, W Chen… - Molecular …, 2023 - Springer
Background Tyrosine kinase and phosphoinositide kinase pathways play important roles in
asthma formation. As a dual tyrosine and phosphoinositide kinase inhibitor, PP121 has …
asthma formation. As a dual tyrosine and phosphoinositide kinase inhibitor, PP121 has …
[HTML][HTML] Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
Inhaled long-acting bronchodilators, including long-acting β 2 agonists (LABAs) and long-
acting muscarinic antagonists (LAMAs) are the mainstay therapy in the treatment of chronic …
acting muscarinic antagonists (LAMAs) are the mainstay therapy in the treatment of chronic …